358 related articles for article (PubMed ID: 30850035)
41. How suitable are JAK inhibitors in treating the inflammatory component in patients with alopecia areata and vitiligo?
Moya EC; Bruinsma RL; Kelly KA; Feldman SR
Expert Rev Clin Immunol; 2022 Mar; 18(3):189-191. PubMed ID: 35107044
[No Abstract] [Full Text] [Related]
42. Tofacitinib therapy for children with severe alopecia areata.
Dai YX; Chen CC
J Am Acad Dermatol; 2019 Apr; 80(4):1164-1166. PubMed ID: 30630026
[No Abstract] [Full Text] [Related]
43. Treatment of Alopecia Areata With Tofacitinib.
Ibrahim O; Bayart CB; Hogan S; Piliang M; Bergfeld WF
JAMA Dermatol; 2017 Jun; 153(6):600-602. PubMed ID: 28355451
[TBL] [Abstract][Full Text] [Related]
44. Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata.
Mackay-Wiggan J; Jabbari A; Nguyen N; Cerise JE; Clark C; Ulerio G; Furniss M; Vaughan R; Christiano AM; Clynes R
JCI Insight; 2016 Sep; 1(15):e89790. PubMed ID: 27699253
[No Abstract] [Full Text] [Related]
45. Tofacitinib for the treatment of alopecia areata and variants in adolescents.
Craiglow BG; Liu LY; King BA
J Am Acad Dermatol; 2017 Jan; 76(1):29-32. PubMed ID: 27816292
[TBL] [Abstract][Full Text] [Related]
46. JAK Inhibitors for Treatment of Alopecia Areata.
Wang EHC; Sallee BN; Tejeda CI; Christiano AM
J Invest Dermatol; 2018 Sep; 138(9):1911-1916. PubMed ID: 30057345
[TBL] [Abstract][Full Text] [Related]
47. Updated Review of Treatment of Androgenetic Alopecia.
Xiao R; Lee LN
Facial Plast Surg Clin North Am; 2024 Aug; 32(3):417-423. PubMed ID: 38936999
[TBL] [Abstract][Full Text] [Related]
48. Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients.
Liu LY; Craiglow BG; Dai F; King BA
J Am Acad Dermatol; 2017 Jan; 76(1):22-28. PubMed ID: 27816293
[TBL] [Abstract][Full Text] [Related]
49. Topical tofacitinib in treatment of alopecia areata.
Ferreira SB; Ferreira RB; Scheinberg MA
Einstein (Sao Paulo); 2020; 18():eAI5452. PubMed ID: 32785452
[No Abstract] [Full Text] [Related]
50. Alopecia Areata: New Treatment Options Including Janus Kinase Inhibitors.
Zheng C; Tosti A
Dermatol Clin; 2021 Jul; 39(3):407-415. PubMed ID: 34053594
[TBL] [Abstract][Full Text] [Related]
51. Clinical significance of Janus Kinase inhibitor selectivity.
Choy EH
Rheumatology (Oxford); 2019 Jun; 58(6):953-962. PubMed ID: 30508136
[TBL] [Abstract][Full Text] [Related]
52. Differences in activation of β-catenin in outer root sheath cells between the type of JAK inhibitor: An alternative mechanism promoting hair growth by JAK inhibitors in alopecia areata.
Shin JM; Sung Y; Hong D; Jung KE; Seo YJ; Kim CD; Lee Y
J Dermatol Sci; 2024 Jun; 114(3):148-150. PubMed ID: 38734548
[No Abstract] [Full Text] [Related]
53. Baricitinib as the first systemic treatment for severe alopecia areata.
Kincaid CM; Arnold JD; Mesinkovska NA
Expert Rev Clin Immunol; 2023 Jun; 19(6):565-573. PubMed ID: 37042112
[TBL] [Abstract][Full Text] [Related]
54. Role of janus kinase inhibitors in the treatment of alopecia areata.
Triyangkulsri K; Suchonwanit P
Drug Des Devel Ther; 2018; 12():2323-2335. PubMed ID: 30100707
[TBL] [Abstract][Full Text] [Related]
55. Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study.
King B; Ko J; Forman S; Ohyama M; Mesinkovska N; Yu G; McCollam J; Gamalo M; Janes J; Edson-Heredia E; Holzwarth K; Dutronc Y
J Am Acad Dermatol; 2021 Oct; 85(4):847-853. PubMed ID: 34090959
[TBL] [Abstract][Full Text] [Related]
56. The Use of Janus Kinase Inhibitors in Alopecia Areata: A Review of the Literature.
Crowley EL; Fine SC; Katipunan KK; Gooderham MJ
J Cutan Med Surg; 2019; 23(3):289-297. PubMed ID: 30688081
[TBL] [Abstract][Full Text] [Related]
57. Successful Treatment of Refractory Alopecia Areata Universalis and Psoriatic Arthritis, But Not of Plaque Psoriasis with Tofacitinib in a Young Woman.
Mrowietz U; Gerdes S; Gläser R; Schröder O
Acta Derm Venereol; 2017 Feb; 97(2):283-284. PubMed ID: 27349217
[No Abstract] [Full Text] [Related]
58. Treatment of Hypereosinophilic Syndrome with Cutaneous Involvement with the JAK Inhibitors Tofacitinib and Ruxolitinib.
King B; Lee AI; Choi J
J Invest Dermatol; 2017 Apr; 137(4):951-954. PubMed ID: 27887955
[No Abstract] [Full Text] [Related]
59. Alopecia areata: What's new in the diagnosis and treatment with JAK inhibitors?
Dainichi T; Iwata M; Kaku Y
J Dermatol; 2024 Feb; 51(2):196-209. PubMed ID: 38087654
[TBL] [Abstract][Full Text] [Related]
60. Case Report: Successful Treatment of Alopecia Universalis With Tofacitinib and Increased Cytokine Levels: Normal Therapeutic Reaction or Danger Signal?
Yu L; Yu H; Zhang S; Hao Y; Zhang S
Front Immunol; 2022; 13():904156. PubMed ID: 35795663
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]